High level delegation from USFDA visits Divi's Labs Choutuppal facility

Hyderabad: Divi's Laboratories Limited has announced that a high-level delegation from the U.S. Food and Drug Administration (USFDA), including Commissioner Dr. Robert M. Califf, India Country Director Dr. Sarah McMullen, and other officials, visited the company's manufacturing facility in Choutuppal, Telangana, India.

The delegation's visit covered a wide range of topics, reflecting the dynamic landscape of the Active Pharmaceutical Ingredient (API) industry, the integration of new technologies, sustainable practices in chemistry, raising manufacturing standards, and ensuring the availability of APIs.

"The company showcased its large-scale world-class production facilities, advanced automated manufacturing capabilities, commitment to innovation, and its crucial role in investing in new technologies to ensure a consistent supply of high-quality APIs," Divi's Labs stated.

“We are proud to participate in this important visit to share our role as a reliable API manufacturer that can deliver large quantities in a relatively short time,” stated Dr. Kiran S Divi, CEO of Divi's Laboratories Limited. “We look forward to continuing to engage and be a part of addressing critical issues that affect the worldwide pharmaceutical industry.”

Divi's Laboratories Limited is a pharmaceutical manufacturing company. The company has global presence in supplying APIs to more than 100 countries.Itcurrently operates two manufacturing locations that are compliant with global regulatory standards and capable of producing annual requirements ranging from 10’s of kilos to 1000’s of tons.

Read also: Emcure Pharma aims to raise USD 400- USD 500 million from IPO planned for next year